Celltrion

Celltrion's reported carbon emissions

Celltrion, a pharmaceutical preparation manufacturer headquartered in South Korea, has reported a total of approximately 74.9 billion kg CO2e emissions in 2024. This figure encompasses Scope 1, 2, and 3 emissions. For 2024, Scope 1 emissions were approximately 27.1 billion kg CO2e, Scope 2 emissions (location-based) were about 52.0 billion kg CO2e, and Scope 3 emissions totalled approximately 42.4 billion kg CO2e. Key contributors to Scope 3 emissions in 2024 included downstream transportation and distribution (approximately 26.9 billion kg CO2e) and upstream transportation and distribution (about 18.1 billion kg CO2e). In 2023, Celltrion's total emissions were approximately 71.3 billion kg CO2e. This comprised Scope 1 emissions of roughly 22.5 billion kg CO2e, Scope 2 emissions (location-based) of approximately 42.3 billion kg CO2e, and Scope 3 emissions totalling around 28.8 billion kg CO2e. Looking at its climate commitments, Celltrion has set a target to reduce greenhouse gas (GHG) emissions by 50% by 2030, using 2020 as a baseline. Furthermore, the company is working towards achieving carbon neutrality by 2050. Celltrion has also announced a Net Zero commitment specifically for its domestic operations, aiming to reduce Scope 1 and 2 emissions by 42% by 2030 and achieve 100% reduction by 2045, based on a 2022 baseline.